Longitudinal Validation of CIRC Technologies
Recruiting · NCT07081711 · Observational (researchers observe without assigning treatment) · Lead sponsor: The Cleveland Clinic
View the official record on ClinicalTrials.gov →What this trial is about
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases. The study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.
Who can take part
Inclusion criteria
- Age ≥ 18 years of age
- Provision of written informed consent
Exclusion criteria
- Vulnerable populations will be excluded from this study including Prisoners
- Other contraindications to CMR imaging to be determined by standard MRI protocols
- Decisionally impaired (e.g., dementia or cognitive disability)
Where it is running
1 location listed across 1 US state.
- Cleveland Clinic - Cleveland, Ohio, United States